Recently, an increasing number of researches demonstrated that aberrant expression of RACK1 was supposed to be prevalent in a wide spectrum of cancers, such as breast cancer [15,26], hepatocellular carcinoma [27], and gastric cancer [28], suggesting that abnormal expression of RACK1 might be correlated with cancer development and progression. Here, RACK1 is linked to cancer.